Krystal Biotech Reports Strong 2025 Financials, $955M in Cash Reserves, and Expansion Plans for Rare Disease Therapies.

Krystal Biotech reported preliminary unaudited financial results for 2025, with VYJUVEK revenue expected to reach $388-389 million and cash reserves at $955 million. The company is advancing a pipeline of rare disease therapies and plans to have at least four marketed medicines by 2030, while maintaining profitability and investing in broader programs. For 2026, Krystal anticipates combined non-GAAP R&D and SG&A expenses between $175 million and $195 million.